C. Ladel

6.3k citations

118 papers · 4.7k indexed · 2 hit papers · h-index 37

Rheumatology top 0.5%
- Osteoarthritis Treatment and Mechanisms 67
- Rheumatoid Arthritis Research and Therapies 14
Immunology top 1%
- Immune Cell Function and Interaction 12
Endocrinology top 1%
Infectious Diseases top 1%
- Tuberculosis Research and Epidemiology 10
Biotechnology top 1%
Pharmacology
- Inflammatory mediators and NSAID effects 18
Surgery
- Total Knee Arthroplasty Outcomes 15
- Knee injuries and reconstruction techniques 13
Molecular Biology
- Fibroblast Growth Factor Research 14

Co-authors: Stefan H. E. Kaufmann Anne‐Christine Bay‐Jensen M.A. Karsdal C Blum Sabine Daugelat Kurt Reifenberg Gudrun Szalay Hans Guehring
Cited by: Rheumatology Immunology Endocrinology
Journals: Osteoarthritis and Cartilage (38 papers)Annals of the Rheumatic Diseases (7 papers)Infection and Immunity (6 papers)
Partner nations: Germany Denmark United States

In The Last Decade

C. Ladel

114 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by C. Ladel

Since Specialization

Citations

This map shows the geographic impact of C. Ladel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Ladel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Ladel more than expected).

Fields of papers citing papers by C. Ladel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Ladel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Ladel. The network helps show where C. Ladel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside C. Ladel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Ladel Line = papers co-authored together C. Ladel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The inflammatory endotype in osteoarthritis: Reflections from the 2024 OARSI clinical trials symposium (CTS) with a special emphasis on feasibility for clinical development Osteoarthritis and Cartilage Open ·M.A. Karsdal,Lucio C. Rovati,J. Tambiah,Olga Kubassova,C. Ladel,Francis Bérenbaum,Anne‐Christine Bay‐Jensen,Faculte De Medecine,Richard F. Loeser,Ali Mobasheri,Virginia B. Kraus	2025	1
2	Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression ACR Open Rheumatology ·Jamie E. Collins,Peter Mesenbrink,暢洋阿久澤,Erik B. Dam,Leticia A. Deveza,F. Eckstein,Ali Guermazi,C. Ladel,Thomas A. Perry,Douglas Robinson,Frank W. Roemer,Christopher J. Swearingen,W. Wirth,Virginia B. Kraus,David J. Hunter	2025	1
3	Biochemical biomarkers of knee osteoarthritis progression: Results from the FNIH biomarkers consortium progress OA study Osteoarthritis and Cartilage Open ·Jamie E. Collins,Douglas Robinson,Nigel Arden,Anne‐Christine Bay‐Jensen,Leticia A. Deveza,M.A. Karsdal,C. Ladel,Thomas A. Perry,Christopher J. Swearingen,David J. Hunter,Virginia B. Kraus	2025	0
4	Cartilage loss is greater in knees with virtual joint replacement status than in matched controls without Osteoarthritis and Cartilage Open ·F. Eckstein,W. Wirth,Ali Guermazi,Frank W. Roemer,Michael C. Nevitt,C. Ladel,Leena Sharma,David J. Hunter,C. Kent Kwoh	2025	1
5	Unbiased analysis of knee cartilage thickness change over three years after sprifermin vs. placebo treatment – A post-hoc analysis from the phase 2B FORWARD study SHILAP Revista de lepidopterología ·F. Eckstein,S. Maschek,W. Wirth,C. Ladel,Asger Reinstrup Bihlet,Chris Knight,Kenneth A. Somberg,A. Medina Herrera	2024	3
6	Is detection of disease-modifying osteoarthritis drug treatment more effective when performing cartilage morphometry without blinding to MR image acquisition order? Osteoarthritis and Cartilage ·F. Eckstein,Hafiz Muhammd Shiraz,S. Maschek,W. Wirth,C. Ladel,Asger Reinstrup Bihlet,Chris Knight,Kenneth A. Somberg,A. Medina Herrera	2024	4
7	Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis ACR Open Rheumatology ·Asger Reinstrup Bihlet,Xiaotao,Kosalaram Goteti,Jesper Sonne,C. Ladel,M.A. Karsdal,Victor Ona,Flavie Moreau,นพภาพร พานิช,Anne‐Christine Bay‐Jensen,Hans Guehring	2024	9
8	Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status? SHILAP Revista de lepidopterología ·M.A. Karsdal,J. Tambiah,Marc C. Hochberg,C. Ladel,Anne‐Christine Bay‐Jensen,Lars Arendt‐Nielsen,Ali Mobasheri,Virginia B. Kraus	2022	8
9	A low repair endotype is predictive for response to FGF-18 treatment: data from the phase II oa forward study Osteoarthritis and Cartilage ·Anne‐Christine Bay‐Jensen,Angela A. Manginelli,M.A. Karsdal,Yunyun Luo,Yi He,M. Michaelis,Hans Guehring,C. Ladel	2021	2
10	Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study Osteoarthritis and Cartilage ·F. Eckstein,Marc C. Hochberg,Grant C. Coomer,Hans Guehring,Flavie Moreau,Victor Ona,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,Y.Z.B. Li,Xiao xue Zhang,C. Ladel,M. Michaelis,Philip G. Conaghan	2020	3
11	ADAMTS-5 degraded cartilage increases tissue turnover in synovial membrane explants and stimulation is inhibited by the anti ADAMTS-5 nanobody, M6495 Osteoarthritis and Cartilage ·Catherine Zilberg,Anne‐Christine Bay‐Jensen,IE Abdel Rhman,En España,M. Michaelis,C. Ladel,M.A. Karsdal,S. Lindemann,正宏天野	2020	1
12	Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects Osteoarthritis and Cartilage ·Xiaotao,Rainer Strotmann,Asger Reinstrup Bihlet,Jesper Sonne,C. Ladel,Flavie Moreau,Hans Guehring	2018	5
13	C1M, C2M, C3M, PRO-C2, and CRPM in serum reflect different potential pathogenetic domains of osteoarthritis, data from check Osteoarthritis and Cartilage ·Anne‐Christine Bay‐Jensen,M.A. Karsdal,C. Ladel,W.E. van Spil	2018	4
14	Association Between Biochemical Markers of Bone Turnover and Bone Changes on Imaging: Data From the Osteoarthritis Initiative Arthritis Care & Research ·Leticia A. Deveza,Virginia B. Kraus,Jamie E. Collins,Ali Guermazi,Frank W. Roemer,M.A. Bowes,Michael C. Nevitt,C. Ladel,David J. Hunter	2016	25
15	Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis Biomarkers ·L. Gy. Szabó,Anne Sofie Siebuhr,T.G. Christiansen,C. Ladel,M.A. Karsdal,Anne‐Christine Bay‐Jensen	2015	34
16	Trajectory of cartilage loss within 4 years of knee replacement – a nested case–control study from the Osteoarthritis Initiative Osteoarthritis and Cartilage ·F. Eckstein,Robert M. Boudreau,Dayelin Machin Martínez,Michael J. Hannon,W. Wirth,Sebastian Cotofana,Ali Guermazi,Frank W. Roemer,Michael C. Nevitt,Markus R. John,C. Ladel,Leena Sharma,David J. Hunter,C. Kent Kwoh	2014	41
17	Characterization of Novel PI3KÎ´ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies Frontiers in Immunology ·Philipp Haselmayer,Montserrat Camps,Imran Hajat,Samer El Bawab,Caroline Waltzinger,Lisa Bruns,Nada Abla,Mark A. Polokoff,Peiyu Zhang,Ilgiz Zamaleev,Bo-Ram Kim,A. Tissen-Raaphorst,Chi Ung Ko,Denise Gretener,Maria Stella Lombardi,Roland Grenningloh,C. Ladel,Lutsenko Mm,P. Gaillard,Hong Ji	2014	24
18	FGF18 augments osseointegration of intra-medullary implants in osteopenic FGFR3-/- mice European Cells and Materials ·Alberto Carli,Chan Gao,M. Dubert,Geumbee Kim,N. N. Kaidisheva,C. Ladel,Edward J. Harvey,D Bricard	2012	15
19	Dysregulation of bacterial proteolytic machinery by a new class of antibiotics Nature Medicine ·Heike Brötz‐Oesterhelt,D. Beyer,Hein‐Peter Kroll,Rainer Endermann,C. Ladel,Werner Schroeder,Berthold Hinzen,Siegfried Raddatz,Holger Paulsen,Kerstin Henninger,Julia E. Bandow,Hans‐Georg Sahl,Harald Labischinski	2005	384
20	Protective role of γ/δ T cells and α/β T cells in tuberculosis European Journal of Immunology ·C. Ladel,Carmen Blum,Joanna Sykurska,Kurt Reifenberg,Stefan H. E. Kaufmann	1995	190

About C. Ladel

C. Ladel is a scholar working on Rheumatology, Anatomy and Pharmacology, having authored 118 papers that have together received 4.7k indexed citations. Recurring topics across this work include Osteoarthritis Treatment and Mechanisms (67 papers), Inflammatory mediators and NSAID effects (18 papers), Total Knee Arthroplasty Outcomes (15 papers), Fibroblast Growth Factor Research (14 papers), Rheumatoid Arthritis Research and Therapies (14 papers), Knee injuries and reconstruction techniques (13 papers), Immune Cell Function and Interaction (12 papers) and Tuberculosis Research and Epidemiology (10 papers). The work is most often cited by research in Rheumatology (1.5k citations), Immunology (1.6k citations) and Endocrinology (307 citations). C. Ladel has collaborated with scholars based in Germany, Denmark and United States. Frequent co-authors include Stefan H. E. Kaufmann, Anne‐Christine Bay‐Jensen, M.A. Karsdal, C Blum, Sabine Daugelat, Kurt Reifenberg, Gudrun Szalay, Hans Guehring, M. Michaelis and Virginia B. Kraus. Their work appears in journals such as Osteoarthritis and Cartilage, Annals of the Rheumatic Diseases, Infection and Immunity, The Journal of Immunology and European Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact